Emma Thompson, Menopause, and Compounded vs. Branded HRT: What's Likely

Why Emma Thompson's Openness About Menopause Matters

Emma Thompson has said things about menopause that most public figures avoid. In a 2021 interview and again in multiple press appearances surrounding her advocacy for menopause education, she described menopause as a subject women are taught to be ashamed of, and called for systemic change in how medicine treats women in midlife. That candor has made her a reference point in the UK menopause conversation.

She has not, to date, published the specifics of her own hormone regimen. What she has made clear is that she believes women deserve real clinical information, not shame. That framing makes her an appropriate lens for a genuinely clinical question: if a 66-year-old British woman with her profile sought menopausal hormone therapy (MHT), would she more likely be on a compounded preparation or a regulated branded product?

The answer requires understanding both options from the ground up.

What "Compounded" Means Versus "Branded"

Branded HRT refers to regulated pharmaceutical products that have passed rigorous safety, efficacy, and quality-control testing by a national medicines authority. In the UK that authority is the Medicines and Healthcare products Regulatory Agency (MHRA). Examples include Evorel patches (transdermal estradiol) and Utrogestan capsules (micronized progesterone), both of which are on the NICE-recommended list.

Compounded HRT is prepared by a pharmacy specifically for an individual patient, usually when a licensed product is unavailable or a patient has a documented allergy to an excipient. Compounded preparations are not subject to the same pre-market approval process and, in the UK, are governed under the Human Medicines Regulations 2012 with pharmacy-specific oversight rather than MHRA product approval.

The NICE Position

NICE guideline NG23 states explicitly that regulated HRT products should be used in preference to non-regulated compounded preparations. The guideline adds that compounded "bioidentical" hormones should not be offered as an alternative to regulated HRT because of the lack of evidence on safety and efficacy. This is the clinical framework that any UK clinician advising Emma Thompson, or any UK woman, would be working within.

The Case for Branded HRT: What the Evidence Shows

Branded estradiol-based HRT has decades of RCT and observational data behind it. The most commonly cited safety concern, the association between combined HRT and breast cancer, is nuanced and dose-dependent, and the absolute risk numbers matter here.

The Women's Health Initiative (WHI) 2002 trial initially alarmed clinicians with a reported increase in breast cancer risk for combined estrogen-progestogen therapy. Subsequent re-analysis, particularly the 2013 WHI reanalysis by Chlebowski et al., showed the risk was concentrated in the synthetic progestin (medroxyprogesterone acetate) arm, and was not seen with estrogen-only therapy in women who had undergone hysterectomy. Later analyses of the WHI data also showed that the absolute excess risk was approximately 8 additional breast cancer cases per 10,000 women per year of combined use, a figure that many clinicians and guideline bodies now view in the context of competing benefits.

Transdermal estradiol carries a meaningfully different risk profile than oral estradiol for venous thromboembolism (VTE). A large UK nested case-control study (Vinogradova et al., BMJ 2019) found that oral estradiol was associated with an increased VTE risk, while transdermal estradiol at standard doses was not associated with a statistically significant increase. That finding has shifted UK prescribing firmly toward transdermal preparations for most women.

Micronized Progesterone vs. Synthetic Progestins

This distinction is one of the most clinically relevant in modern menopause medicine. Micronized progesterone (the active ingredient in Utrogestan) is structurally identical to endogenous progesterone and has a different receptor-binding profile from synthetic progestins such as medroxyprogesterone acetate (MPA) or norethisterone.

The E3N French cohort study (Fournier et al., 2008) followed 80,377 postmenopausal women and found that estrogen combined with micronized progesterone was not associated with a significantly increased breast cancer risk over the study period, in contrast to estrogen combined with synthetic progestins. This finding is observational and should be interpreted accordingly, but it has been influential in shaping current UK and French prescribing patterns.

A woman with Emma Thompson's public-health awareness, working with a well-informed UK menopause specialist, would almost certainly be offered transdermal estradiol plus micronized progesterone as a first-line regimen. That is the combination recommended by both NICE NG23 and the British Menopause Society (BMS), and it is the one with the most favorable safety profile in current evidence.

Specific Branded Options Available in the UK

• Transdermal estradiol: Evorel 25, 50, 75, or 100 patches (changed twice weekly), or Oestrogel/Lenzetto gel/spray (applied daily to skin)
• Micronized progesterone: Utrogestan 100 mg or 200 mg capsules (taken orally or vaginally)
• Combined patches: Evorel Conti or Evorel Sequi (norethisterone-containing; less favored due to progestin concerns)

The Case for Compounded HRT: When It Has a Role

Compounded preparations are not categorically harmful or fraudulent. There are specific clinical situations where they fill a genuine gap.

If a woman cannot tolerate the excipients in a licensed product, is responding poorly to all available doses of regulated estradiol, or requires a formulation not commercially available (such as a specific low-dose estriol cream for genitourinary syndrome of menopause, or GSM), a licensed compounding pharmacy can prepare a tailored product.

In the US context, compounded "bioidentical" hormones are heavily marketed, often combined into a single cream containing estradiol, estrone, estriol, progesterone, testosterone, and DHEA, in proportions determined by salivary hormone testing. The Endocrine Society's 2016 scientific statement on compounded bioidentical hormones concluded that salivary hormone testing is not a reliable basis for prescribing and that multi-hormone compounded preparations have not been proven superior to regulated products.

Emma Thompson is British. The UK compounding field is narrower and more tightly regulated than the US one. A British woman seeing a private menopause specialist (which, given Thompson's resources, is entirely plausible) would be operating in an environment where compounded preparations are an exception, not a default. The more dramatic "bespoke bioidentical" prescribing culture is largely a US and Australia-adjacent phenomenon.

The Evidence Gap for Compounded Preparations

Compounded preparations lack phase III RCT data. They are not tested for batch-to-batch consistency in the way regulated pharmaceuticals are. The FDA's 2019 guidance on compounded drug products flagged that compounded hormone preparations may contain doses that are too high, too low, or inconsistent across preparations. Women deserve to know this.

The table below provides a clinical comparison framework for evaluating branded vs. Compounded HRT, built specifically for the questions a perimenopausal or postmenopausal woman should ask her prescriber.

| Feature | Branded / Regulated HRT | Compounded HRT | |---|---|---| | Regulatory approval | Yes (MHRA/FDA) | No pre-market approval | | RCT evidence base | Extensive (WHI, E3N, MWS) | Minimal | | Batch-to-batch consistency | Tested, required | Not routinely verified | | NICE-recommended | Yes | No | | Appropriate for most women | Yes | Narrow indications | | Salivary hormone testing | Not required | Often marketed with it | | Typical UK cost | Covered by NHS or low private cost | Higher private cost |

Life Stage Breakdown: Who Is Asking This Question?

Emma Thompson's situation (post-menopause, over 60, likely well past peak symptom burden) differs from many women who are searching her name in the context of their own hormone decisions. Here is how the compounded-vs-branded question lands differently depending on where you are in your reproductive life.

Perimenopause (Typically Ages 45-52)

Perimenopause is the transition phase, and it is where symptoms are often most new. Cycles become irregular, estrogen fluctuates dramatically, and vasomotor symptoms, sleep disruption, mood changes, and brain fog appear. The Menopause Society's 2023 position statement confirms that MHT is the most effective treatment for vasomotor symptoms and should be offered to healthy symptomatic women without contraindications.

Perimenopausal women who are still cycling need a different progesterone regimen than postmenopausal women (sequentially dosed rather than continuous). This nuance is easily handled with regulated products and does not require compounding.

Post-Menopause (Age 51 Plus on Average)

Post-menopause is where both Emma Thompson currently sits and where the WHI data was largely generated. The 2022 updated Menopause Society position reaffirmed that for women under 60 or within 10 years of menopause, the benefits of MHT outweigh risks for most women without contraindications. For women over 60 who are starting MHT for the first time, the risk-benefit calculation is more individualized.

If Thompson started HRT in her early 50s and continued, that is consistent with current guidance. If she started de novo at 65, that would require a more careful individual risk discussion, particularly regarding cardiovascular disease.

Reproductive Years and Trying to Conceive

This life stage is not relevant to Emma Thompson's current situation, but many women searching menopause content are themselves perimenopausal and still technically in their reproductive years. Perimenopause does not reliably prevent pregnancy. ACOG Practice Bulletin No. 141 notes that contraception should be continued until menopause is confirmed (12 consecutive months of amenorrhea), because ovulation can still occur during the transition.

HRT formulations used in perimenopause are NOT reliable contraception. A woman in her late 40s using HRT for symptom management still needs a separate contraceptive method if she is not comfortable with an unintended pregnancy.

Pregnancy, Lactation, and Contraception Safety

This section is included because the article covers hormone therapy decisions, and some readers are perimenopausal women still in their reproductive years.

Estradiol (all forms): Contraindicated in confirmed pregnancy. Estradiol is a Category X equivalent under older US classification; it is not compatible with pregnancy and should not be used. If you discover you are pregnant while taking HRT, stop the preparation and contact your clinician immediately.

Micronized progesterone (Utrogestan): Also contraindicated in pregnancy as a continuous HRT preparation, though progesterone supplementation in early pregnancy is used in a separate clinical context (threatened miscarriage, IVF support) under specific medical supervision. The HRT formulation is distinct from luteal-support progesterone; do not conflate the two.

Lactation: Postmenopausal HRT is not a lactation scenario. For completeness: systemic estradiol suppresses prolactin and is not appropriate in women who are breastfeeding.

Contraception requirement: Any woman using HRT in perimenopause who could still conceive should use a separate non-hormonal or progestin-only contraceptive method. The combined oral contraceptive pill is sometimes used in early perimenopause to manage symptoms and provide contraception simultaneously, but this is a different pharmacological approach from MHT, carries different risks, and should be distinguished clearly.

Female-Specific Physiology: Why Women Process These Hormones Differently

Women's bodies do not simply need hormones replaced in a generic sense. The route of administration, the specific molecular form, and the timing relative to menopause all interact with female-specific cardiovascular, metabolic, and breast physiology.

First-pass hepatic metabolism is avoided by transdermal estradiol. Oral estradiol undergoes significant liver metabolism, raising sex hormone-binding globulin (SHBG), triglycerides, and coagulation factors. Transdermal delivery bypasses this, which is why the VTE risk profile differs so markedly between the two routes. Canonico et al. (2010) in Thrombosis and Haemostasis confirmed transdermal estradiol was not associated with increased VTE risk in a pooled analysis of French epidemiological studies.

The timing hypothesis (also called the healthy cell hypothesis or the critical window) holds that estrogen is cardioprotective when initiated close to menopause but may be neutral or mildly harmful when started years after. The KEEPS trial (Harman et al., 2014) and the ELITE trial (Hodis et al., 2016, NEJM) both supported this window concept, showing that women randomized to estradiol within 6 years of menopause had less carotid intima-media thickness progression than those randomized more than 10 years out.

Metabolic effects in PCOS: Women with a history of polycystic ovary syndrome (PCOS) often enter perimenopause with pre-existing insulin resistance and dyslipidemia. Transdermal estradiol's more neutral hepatic metabolic profile may be particularly appropriate for this group, though head-to-head trial data in PCOS-specific menopause cohorts remain thin. This is an evidence gap: women with PCOS are underrepresented in major menopause trials.

Bone health: Estrogen is the primary brake on osteoclast-mediated bone resorption. After menopause, bone mineral density falls at approximately 1-2% per year. The USPSTF 2018 guidance on osteoporosis screening recommends bone density screening for women aged 65 and older. HRT preserves bone density, though it is not currently first-line specifically for osteoporosis prevention given the cardiovascular and breast considerations.

Conditions HRT Touches That Are Relevant to Women

Menopause intersects with multiple female-specific health domains that rarely get integrated into a single conversation.

Genitourinary Syndrome of Menopause (GSM)

GSM, formerly called vulvovaginal atrophy or atrophic vaginitis, affects an estimated 45-63% of postmenopausal women and produces vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs. Systemic HRT may partially address GSM, but local low-dose vaginal estradiol (cream, ring, or tablet) is highly effective with minimal systemic absorption. This is one of the clearer use cases for a compounded preparation IF a licensed vaginal product is unavailable or poorly tolerated, though licensed options (Vagifem, Estring, Estrace) exist in most markets.

Female Pattern Hair Loss and Hormonal Acne

Both are estrogen-sensitive conditions that can worsen dramatically in perimenopause and post-menopause. HRT does not uniformly treat hair loss, but stabilizing the hormonal environment often slows the androgenic acceleration seen in menopause. The evidence here is observational rather than trial-based.

Sexual Health and HSDD

Hypoactive sexual desire disorder (HSDD) has a specific pharmacological treatment (flibanserin in premenopausal women, or off-label in postmenopausal women), but many postmenopausal women find that addressing estrogen deficiency and GSM substantially improves sexual function. Testosterone supplementation (off-label in most markets) is also discussed in this context. The Global Consensus Statement on testosterone therapy for women (2019) supports its use for HSDD in postmenopausal women at physiologic doses.

Who Is This Right For (and Who Should Be Cautious)

Strong candidates for branded regulated HRT

• Women aged 45-60 with bothersome vasomotor symptoms
• Women with premature ovarian insufficiency (POI), at any age
• Women with significant GSM symptoms
• Women with high fracture risk and no contraindications to estrogen
• Women who want the clearest risk-benefit data available

Women who may need individualized consideration

• Women with a personal history of estrogen-receptor-positive breast cancer (generally a contraindication; discuss with oncologist)
• Women with a history of VTE or thrombophilia (transdermal route may still be appropriate; requires specialist input)
• Women with active liver disease (transdermal preferred; oral estrogen contraindicated)
• Women who started menopause more than 10 years ago and are starting HRT for the first time

Women for whom compounded preparations might add value

• Those with documented allergy to an excipient in a licensed product
• Those requiring a dose or delivery format genuinely not available in a regulated product
• Those needing compounded vaginal estriol where licensed products are unavailable

What Emma Thompson's Protocol Is Actually Likely to Be

Based on the public record: Emma Thompson has not disclosed a specific regimen. What she has disclosed is a commitment to women having access to information, and a frustration with the shame and silence that has historically surrounded menopause.

Given her age (66), her UK base, the clinical context of NICE NG23 guidance, and the strong evidence base for transdermal estradiol plus micronized progesterone, the most clinically plausible scenario is that she uses a regulated branded transdermal estradiol preparation (patch or gel) combined with Utrogestan (micronized progesterone). This is the standard of care a well-resourced UK woman with good access to private menopause specialists would receive.

A fully custom compounded "bioidentical" preparation of the American concierge-medicine variety is less likely given the UK regulatory environment, the NICE guidance her clinicians would follow, and the evidence base that any informed advocate would want on her side.

Her public statements are, in a sense, an endorsement of evidence-based medicine over the unregulated wellness market. That aligns more with regulated HRT than with compounded preparations lacking trial data.